Zentiva launches Buspirone 15mg and 30mg strength tablets


Share post:

Zentiva, one of the leading developers and suppliers of prescription medicines and consumer brands has launched 15 mg and 30 mg Buspirone tablets.

This medication is indicated for the treatment of short-term management of anxiety disorders and the relief of symptoms of anxiety with or without accompanying symptoms of depression.

Luke Hart, General Manager commented, “Zentiva is excited to announce this new addition to our Value Added Medicines portfolio, continuing to meet the unfulfilled needs of patients.”

He continues, “the launch of our 15mg and 30mg Buspirone Tablets will enable more flexible and accurate dosing – allowing for simple and convenient dosing regimens for patients with anxiety disorders.”


Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...